Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors
The influence of COVID-19 vaccination on the efficacy and safety of immune checkpoint inhibitors (ICIs) in lung cancer treatment is not well understood. A cohort of 394 lung cancer patients treated with PD-1/PD-L1 inhibitors was analyzed. The incidence and types of irAEs were recorded, and the relat...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2539593 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849770818454683648 |
|---|---|
| author | Ping Luo Jiasi Liu Zhan Wang Chenwei Liao Lei She Ting Zou Juan Chen Zhaoqian Liu |
| author_facet | Ping Luo Jiasi Liu Zhan Wang Chenwei Liao Lei She Ting Zou Juan Chen Zhaoqian Liu |
| author_sort | Ping Luo |
| collection | DOAJ |
| description | The influence of COVID-19 vaccination on the efficacy and safety of immune checkpoint inhibitors (ICIs) in lung cancer treatment is not well understood. A cohort of 394 lung cancer patients treated with PD-1/PD-L1 inhibitors was analyzed. The incidence and types of irAEs were recorded, and the relationship between COVID-19 vaccination and progression-free survival (PFS) was assessed using univariate and multivariate analyses. Among the 394 patients, 44% (171 cases) experienced multiple irAEs, 29% (114 cases) had a single type of irAE, and 27% (108 cases) reported no adverse reactions. The most common irAEs included thyroid-related events (hypothyroidism: 18%, hyperthyroidism: 11%), skin toxicity (16%), cardiovascular toxicity (14%), skeletal muscle toxicity (8%), glycemic endocrine toxicity (7%), and pneumonia (6%). COVID-19 vaccination was associated with a decrease in the incidence of immune-related arthritis and myocarditis, while other irAEs such as pneumonia, dermatitis/rash, myositis, oculopathy, diabetes, colitis, nephritis, hypothyroidism, hyperthyroidism, hypophysitis, and transaminitis were unaffected. No significant correlation was found between COVID-19 vaccination and PFS in both univariate and multivariate analyses. COVID-19 vaccination does not increase the incidence of irAEs nor affect the PFS of lung cancer patients receiving ICIs treatment. |
| format | Article |
| id | doaj-art-68eeff38b4664041b060f065530778fc |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-68eeff38b4664041b060f065530778fc2025-08-20T03:02:52ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2539593Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitorsPing Luo0Jiasi Liu1Zhan Wang2Chenwei Liao3Lei She4Ting Zou5Juan Chen6Zhaoqian Liu7Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, P. R. ChinaDepartment of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, P. R. ChinaLung Cancer and Gastrointestinal Unit, Department of Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, P. R. ChinaXiangya School of Pharmacy, Central South University, Changsha, P. R. ChinaDepartment of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, P. R. ChinaNational Institution of Drug Clinical Trial, Xiangya Hospital, Central South University, Changsha, P. R. ChinaDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, P. R. ChinaDepartment of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, P. R. ChinaThe influence of COVID-19 vaccination on the efficacy and safety of immune checkpoint inhibitors (ICIs) in lung cancer treatment is not well understood. A cohort of 394 lung cancer patients treated with PD-1/PD-L1 inhibitors was analyzed. The incidence and types of irAEs were recorded, and the relationship between COVID-19 vaccination and progression-free survival (PFS) was assessed using univariate and multivariate analyses. Among the 394 patients, 44% (171 cases) experienced multiple irAEs, 29% (114 cases) had a single type of irAE, and 27% (108 cases) reported no adverse reactions. The most common irAEs included thyroid-related events (hypothyroidism: 18%, hyperthyroidism: 11%), skin toxicity (16%), cardiovascular toxicity (14%), skeletal muscle toxicity (8%), glycemic endocrine toxicity (7%), and pneumonia (6%). COVID-19 vaccination was associated with a decrease in the incidence of immune-related arthritis and myocarditis, while other irAEs such as pneumonia, dermatitis/rash, myositis, oculopathy, diabetes, colitis, nephritis, hypothyroidism, hyperthyroidism, hypophysitis, and transaminitis were unaffected. No significant correlation was found between COVID-19 vaccination and PFS in both univariate and multivariate analyses. COVID-19 vaccination does not increase the incidence of irAEs nor affect the PFS of lung cancer patients receiving ICIs treatment.https://www.tandfonline.com/doi/10.1080/21645515.2025.2539593COVID-19 vaccineimmune checkpoint inhibitorirAElung cancer |
| spellingShingle | Ping Luo Jiasi Liu Zhan Wang Chenwei Liao Lei She Ting Zou Juan Chen Zhaoqian Liu Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors Human Vaccines & Immunotherapeutics COVID-19 vaccine immune checkpoint inhibitor irAE lung cancer |
| title | Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors |
| title_full | Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors |
| title_fullStr | Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors |
| title_full_unstemmed | Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors |
| title_short | Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors |
| title_sort | effects of covid 19 vaccination on iraes and prognosis in lung cancer patients receive pd l 1 inhibitors |
| topic | COVID-19 vaccine immune checkpoint inhibitor irAE lung cancer |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2539593 |
| work_keys_str_mv | AT pingluo effectsofcovid19vaccinationoniraesandprognosisinlungcancerpatientsreceivepdl1inhibitors AT jiasiliu effectsofcovid19vaccinationoniraesandprognosisinlungcancerpatientsreceivepdl1inhibitors AT zhanwang effectsofcovid19vaccinationoniraesandprognosisinlungcancerpatientsreceivepdl1inhibitors AT chenweiliao effectsofcovid19vaccinationoniraesandprognosisinlungcancerpatientsreceivepdl1inhibitors AT leishe effectsofcovid19vaccinationoniraesandprognosisinlungcancerpatientsreceivepdl1inhibitors AT tingzou effectsofcovid19vaccinationoniraesandprognosisinlungcancerpatientsreceivepdl1inhibitors AT juanchen effectsofcovid19vaccinationoniraesandprognosisinlungcancerpatientsreceivepdl1inhibitors AT zhaoqianliu effectsofcovid19vaccinationoniraesandprognosisinlungcancerpatientsreceivepdl1inhibitors |